Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer

NCT04348643 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.

NCT NCT04348643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04348643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer
Lead sponsor
Chongqing Precision Biotech Co., Ltd
Phase
Phase 1/2
Overall status
Withdrawn
Start date
February 20, 2020
Completion date
April 30, 2024
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer, solid tumor